I agree that this site is using cookies. You can find further informations here.
X
Kros, J M
~ 900  results:
Search for persons X
?
1

P10.12.B MOLECULAR MECHANISMS INVOLVED IN THE DEVELOPMENT O..:

Najjary, S ; Kros, J M ; de Koning, W.
Neuro-Oncology.  25 (2023)  Supplement_2 - p. ii64-ii64 , 2023
Link: https://doi.org/10.1093/..
 
?
2

Medulloblastoma in adults: evaluation of the Dutch society ..:

Bleeker, L. ; Kouwenhoven, M. C. M. ; de Heer, I....
Journal of Neuro-Oncology.  162 (2023)  1 - p. 225-235 , 2023
Link: https://doi.org/10.1007/..
 
?
3

KS03.7.A INDEPENDENT PROGNOSTIC ROLE OF METHYLATION CLASS I..:

Maas, S L N ; Sievers, P ; Weber, D...
Neuro-Oncology.  25 (2023)  Supplement_2 - p. ii5-ii6 , 2023
Link: https://doi.org/10.1093/..
 
?
4

P14.03.A DO GLIOMA PATIENTS PRODUCE AUTO-ANTIBODIES FOR GLI..:

Zeneyedpour, L ; Stingl, C ; Kros, J M..
Neuro-Oncology.  25 (2023)  Supplement_2 - p. ii105-ii106 , 2023
Link: https://doi.org/10.1093/..
 
?
5

The value of prognostic and predictive parameters in early-..:

Wolf, J.L. ; Trandafir, T.E. ; Akram, F....
Lung Cancer.  176 (2023)  - p. 112-120 , 2023
Link: https://doi.org/10.1016/..
 
?
6

JS04.6.A CLINICAL PRESENTATION OF "MOLECULAR GLIOBLASTOMA" ..:

Wijnenga, M M J ; Maas, S L N ; van Dis, V...
Neuro-Oncology.  25 (2023)  Supplement_2 - p. ii8-ii9 , 2023
Link: https://doi.org/10.1093/..
 
?
7

Identification, validation and biological characterisation ..:

White, K. ; Connor, K. ; Meylan, M....
Annals of Oncology.  34 (2023)  3 - p. 300-314 , 2023
Link: https://doi.org/10.1016/..
 
?
8

OS08.1.A Integrative molecular analysis of matched primary ..:

Vallentgoed, W R ; Hoogstrate, Y ; van Dijk, E...
Neuro-Oncology.  24 (2022)  Supplement_2 - p. ii18-ii18 , 2022
Link: https://doi.org/10.1093/..
 
?
9

P05.04.A Disconcordance between different molecular methods..:

Vallentgoed, W ; van Dijk, E ; van den Bent, M J...
Neuro-Oncology.  24 (2022)  Supplement_2 - p. ii37-ii37 , 2022
Link: https://doi.org/10.1093/..
 
?
10

OS07.8.A Prognosis in IDH-mutant glioma: the role of extent..:

van der Vaart, T ; Wijnenga, M M J ; van Garderen, K A...
Neuro-Oncology.  24 (2022)  Supplement_2 - p. ii17-ii17 , 2022
Link: https://doi.org/10.1093/..
 
?
11

P11.69.B IDH1/2wildtype gliomas grade 2 and 3 with molecula..:

van Opijnen, M P ; Tesileanu, C M S ; Dirven, L...
Neuro-Oncology.  24 (2022)  Supplement_2 - p. ii74-ii74 , 2022
Link: https://doi.org/10.1093/..
 
?
12

OS05.2.A MGMT promoter status in IDH1/2 mutant anaplastic a..:

Tesileanu, C M S ; French, P J ; Sanson, M...
Neuro-Oncology.  23 (2021)  Supplement_2 - p. ii6-ii7 , 2021
Link: https://doi.org/10.1093/..
 
?
13

OS05.5.A Methylation analysis of matched primary and recurr..:

Vallentgoed, W R ; Niers, J M ; van den Bent, M J...
Neuro-Oncology.  23 (2021)  Supplement_2 - p. ii7-ii8 , 2021
Link: https://doi.org/10.1093/..
 
?
14

Spinal meningiomas: Treatment outcome and long-term follow-..:

Kwee, L.E. ; Harhangi, B.S. ; Ponne, G.A....
Clinical Neurology and Neurosurgery.  198 (2020)  - p. 106238 , 2020
Link: https://doi.org/10.1016/..
 
?
15

P11.08 Defining EGFR amplification status for clinical tria..:

French, P ; Eoli, M ; Sepulveda, J...
Neuro-Oncology.  21 (2019)  Supplement_3 - p. iii43-iii44 , 2019
Link: https://doi.org/10.1093/..
 
1-15